CRP and schizophrenia: Meta-analysis suggests that evidence of immune activation, defined by elevated CRP levels, is present in a quarter to one-third of patients with schizophrenia.38 A randomised controlled trial of infliximab, an antitumour necrosis factor alpha mAb, reported that antidepressant response was associated with higher CRP levels at baseline,39 suggesting that patients with evidence of immune activation may be better candidates for immunotherapy trials.